Eli Lilly’s international GLP-1 business is booming, giving investors another reason to stick with the stock.
The United States remains the largest and most lucrative pharmaceutical market in the world. But at this stage of Eli Lilly’s crucial obesity-drug business, the greenest pastures are currently overseas. Indianopolis-based Lilly’s blistering GLP-1 gro… [11984 chars]
Source: CNBC | Published: 2026-07-09T16:12:14Z
Credit: CNBC
